PHARMANIAGA BHD
KLSE (MYR): PHARMA (7081)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.355
Today's Change
-0.005 (1.39%)
Day's Change
0.355 - 0.365
Trading Volume
697,200
Financial
T4Q
31-Mar-2021
2020
31-Mar-2021
2019
31-Mar-2021
2018
31-Mar-2021
2017
31-Mar-2021
Total assets
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current assets
238
1000
110
900
600
Cash & equivalents
238
1000
110
900
600
Short term investments
238
1000
110
900
600
Total receivables, net
238
1000
110
900
600
Accounts receivable - trade, net
238
1000
110
900
600
Other receivables
238
1000
110
900
600
Total inventory
238
1000
110
900
600
Inventories - work in progress
238
1000
110
900
600
Inventories - progress payments & other
238
1000
110
900
600
Inventories - finished goods
238
1000
110
900
600
Inventories - raw materials
238
1000
110
900
600
Total non-current assets
238
1000
110
900
600
Long term investments
238
1000
110
900
600
Note receivable - long term
238
1000
110
900
600
Investments in unconsolidated subsidiaries
238
1000
110
900
600
Other investments
238
1000
110
900
600
Net property/plant/equipment
238
1000
110
900
600
Gross property/plant/equipment
238
1000
110
900
600
Accumulated depreciation, total
238
1000
110
900
600
Deferred tax assets
238
1000
110
900
600
Net intangible assets
238
1000
110
900
600
Other current assets, total
238
1000
110
900
600
Total liabilities
238
-1.64%
1000
+11.55%
110
+81.66%
900
-13.16%
600
+235.36%
Total current liabilities
-238
-1000
-110
-900
-600
Total non-current liabilities
-238
-1000
-110
-900
-600
Long term debt
238
1000
110
900
600
Long term debt excl. lease liabilities
238
1000
110
900
600
Capital and operating lease obligations
238
1000
110
900
600
Provision for risks & charge
-238
-1000
-110
-900
-600
Deferred tax liabilities
-238
-1000
-110
-900
-600
Other liabilities, total
-238
-1000
-110
-900
-600
Total equity
-238
-1.64%
-1000
+11.55%
-110
+81.66%
-900
-13.16%
-600
+235.36%
Total liabilities & shareholders' equities
238B
1000B
110B
900B
600B
Total debt
238
1000
110
900
600
Book value per share
-238
-1000
-110
-900
-600
Discussions
6 people like this. Showing 50 of 14,146 comments
got nothing to do with Biden drops from presidential race .. people over here still need pills and treatment. Pelaung to top up😅
2024-07-22 11:42
Is there a dateline set by BURSA for PN17 status to be removed? Anyone knows?
2024-08-01 08:16
Michael Kwok dari Kenanga ? 🤔
https://klse.i3investor.com/web/pricetarget/research/72061
2024-08-02 18:29
rare opportunity to grab at this level.. medical sector will not be affected by US burst.
2024-08-05 15:05
People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event
2024-08-05 15:15
OTHERS | https://www.klsescreener.com/v2/announcements/view/7963613
Omg resignation of auditors
2024-09-23 13:29
*** All look well.
*** Timely announcement: E&Y.
*** Improving biz trends.
*** Should be hot upon PN17 exit!
2 months ago
I think market are just waiting for uplift of PN17. Look at Dpharma, already up so much. Soon will be us.
2 months ago
bursa so lazy, its been mora than 6 month, not reply ..PMx should bur$4 activities which always favour the speculators!! so lazy la..
2 months ago
this company falls under strategic and security for the nation, asclong as no corrupt or mismanagmnt.. gahmen will always give support. Previous disaster due to previous govt request to stockile vaccine ..in the end, they dont buy. Ltat n bousted..may be replaced by khazanah or pnb, kwsp.
1 month ago
this QR sure outstanding from govt supply and indonesia business.. Pharma even sub-con Duopharma
3 weeks ago
why you should buy at current price.. starting this year.. this company can produce and supply INSULIN!!.. next year current Biocon-Duopharma contract expired, and gov will have option to split at least to this company.
3 weeks ago
Extremely good QR result~ next will be announcement plan to exit pn17.. more upsides coming
3 weeks ago
company value $500m, one QR already $100m !! ... some more out from pn7 soon. .. end of this week 50 cents. End of this year 60-70 cents!! .. obat list from 600 to 800 items. And vaccine+ Insuline. RM 1 company.
3 weeks ago
any one can feedback or commend about the regulation plan ? is it a good thing or bad thing for shareholder ?
3 weeks ago
now everybody will scramble to get a piece of this company.. regulation plan approved, profit improving, insulin will generate lots of profits, ..TP 1.0 year end !
1 week ago
For pharmaceutical players, innovations like Pharmaniaga Bhd’s (KL:PHARMA) locally produced recombinant insulin, which received National Pharmaceutical Regulatory Agency (NPRA) approval in November, is set to launch in the first quarter of 2025, which reflects the sector’s evolution towards meeting chronic disease demands.
https://theedgemalaysia.com/node/737010
1 week ago
post pandemic ramai sakit teruk, gula takda cukai betapa lama, kini ramai ada kencing manis, big demand for ubat lagipun, aging society in malaysia terlalu ramai orang tua, sakit, ubat up up up
1 week ago
msia jugak negara teramai si gemuk di asia... good biz for phrma ramai ada penyakit kronik ya... ubat demand up like crazy diba
1 week ago
Profitable
<%-- for fixing scrollbar--%>
Save Print Back
7081 PHARMA PHARMANIAGA BHD
Quarterly rpt on consolidated results for the financial period ended 30/09/2024
Quarter: 3rd Quarter
Financial Year End: 31/12/2024
Report Status: Unaudited
Submitted By:
Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period
30/09/2024 30/09/2023 30/09/2024 30/09/2023
RM '000 RM '000 RM '000 RM '000
1 Revenue 1,029,822 885,486 2,833,037 2,614,674
2 Profit/Loss Before Tax 138,485 (56,259) 180,863 (40,724)
3 Profit/(loss) attributable to ordinary equity holders of the parent 101,032 (49,339) 129,475 (44,731)
4 Net Profit/Loss For The Period 101,319 (49,047) 131,344 (43,957)
5 Basic Earnings/Loss Per Shares (sen) 7.01 (3.67) 8.98 (3.33)
6 Dividend Per Share (sen) 0.00 0.00 0.00 0.00
As At End of Current Quarter As At Preceding Financial Year End
7 Net Assets Per Share (RM) (0.1214) (0.2075)
Remarks:
You are advised to read the entire contents of the announcement or attachment.
To read the entire contents of the announcement or attachment, please access
the Bursa website at http://www.bursamalaysia.com
26/11/2024 07:00 AM
Ref Code: 202411263100074
4 days ago
Post a Comment
Featured Posts
Latest Videos
Apps
Top Articles
1
Stock Market Enthusiast
Top 3 AI/Data Center Newsflow for the 3rd Week of December - #TENAGA, #YTL, #YTLPOWER
2
Rakuten Trade Research Reports
3
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
6
Good Articles to Share
Gaza ceasefire deal 'closer than ever', says Hamas and two allies
7
Good Articles to Share
Ryan Serhant makes bold pitch to fix the housing ‘affordability crisis’
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
soon9913
Don't all in, get ready some money to subscribe the right issue
2024-07-21 15:12